English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Biomimetic hybrid particles based on amlodipine-imprinted poly(methacrylic acid-co-ethylene glycol dimethacrylate) (MIP) are developed by free radical polymerization of the monomers and crosslinkers in the presence of silica nanoparticles. Atomic force microscopy is used to study the distribution and surface morphology of MIP-silica hybrid particles. The responsive properties are studied by exposing the synthesized MIP-silica hybrid material to standard amlodipine drug solution and consequently monitoring the decrease in drug concentration. The control material, i.e., nonimprinted polymer- (NIP-) silica hybrid particles, exhibits much lower response during the drug rebinding assay suggesting the lack of functionality due to the absence of imprinting effects. The selectivity of MIP-silica hybrid particles is evaluated by examining the aspirin uptake that shows lower absorbance shifts for aspirin solution compared to amlodipine. It indicates a higher sensitivity of MIP-silica hybrid particles toward targeted pharmaceutical drug recognition and also exhibits their potential for drug assay in multiplex biological samples. Furthermore, MIP-silica hybrid particles used in the drug rebinding assay can be recovered and regenerated for subsequent tests without losing recognition properties.

Molecularly Imprinted Polymer-Silica Hybrid Particles for Biomimetic Recognition of Target Drugs